Evotec refines its drug discovery strategy, shares in the TecDAX biotech field
23.06.2026 - 08:18:02 | ad-hoc-news.de
By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-23, 08:15.
Evotec (DE0005664809) continues to build its partnered drug discovery and development model as a TecDAX-listed biotech name. The long-term strategy with global pharma partners and a broad pipeline remains central to how the shares trade on Xetra, according to recent analyst and market commentary.
How Evotec earns its money
Evotec positions itself as a drug discovery and development partner rather than a classic single-product biotech, working on fee-for-service, milestone and royalty structures with large groups such as Bayer and Bristol Myers Squibb. The company’s most recent annual report describes a portfolio of more than 130 proprietary and partnered R&D projects across multiple therapeutic areas, including neuroscience, metabolic diseases and oncology, with revenue primarily stemming from research services and milestone income.Evotec annual report
Position in the German biotech universe
On the German market, Evotec stands alongside listed life science peers such as MorphoSys and Qiagen, but differs through its focus on external partnerships and platform-based discovery rather than owning a single late-stage lead asset. In TecDAX comparisons compiled by market-data services, Evotec is typically classified in the health care and biotechnology segment, where revenue growth and pipeline breadth are standard benchmarks used by analysts in Frankfurt and London to compare the stock with sector names like Morphosys and Qiagen.Börse Frankfurt profile
All news and key data on the Evotec shares
Further company reports, regulatory filings and background articles provide additional context for the Evotec shares on the German market.
The product behind the stock
A concrete example of Evotec’s offering is its fully integrated drug discovery platform, which covers target identification, hit finding, medicinal chemistry, preclinical development and early clinical support for pharma clients. This platform, which is applied in collaborations with companies such as Bayer in endometriosis and chronic cough programs, underpins Evotec’s aim of earning recurring service revenue plus future royalties from successful partner-launched medicines.Evotec platform overview
Where the Evotec shares trade
The Evotec shares (DE0005664809) trade on Xetra at 19.80 euros as of 2026-06-23, 10:00, placing the company firmly in the TecDAX health care segment on the German market.
Key data on the Evotec shares
- Company: Evotec SE
- ISIN: DE0005664809
- WKN: 566480
- Ticker: EVT
- Trading venue: Xetra
- Price (as of 2026-06-23, 10:00): 19.80 euros
- Market cap: 3.5 billion euros (as of 2026-06-23)
- Sector / industry: Health Care / Biotechnology
- Index membership: TecDAX
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or any other kind of financial service.
